EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Sponsor
Daiichi Sankyo
Study ID
NCT05458401
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trastuzumab deruxtecan — DRUG
    No drug will be administered during this study.

Study Details

A named patient program (NPP) was initiated to allow patients with an unmet medical need to access trastuzumab deruxtecan (T-DXd) treatment. To gain early insights on the use of T-DXd outside of a trial setting, patients with advanced/metastatic HER2+ breast cancer receiving treatment (or previously treated) with T-DXd through the NPP will be invited to participate.

Key Dates

Start date
Nov 11, 2022
Status verified
Mar 2024
Primary completion
Dec 1, 2023
Completion
Dec 1, 2023

Study Design

Enrollment
256 participants (actual)

Arms

  • Arm: Trastuzumab Deruxtecan (T-DXd) Cohort
    Patients with advanced/metastatic HER2-positive breast cancer who are receiving treatment (or previously treated) with trastuzumab deruxtecan (T-DXd).

Primary Outcome Measure

Real-World Time-to-Treatment Discontinuation In Participants Treated With Trastuzumab Deruxtecan (T-DXd) [ Time Frame: From the time from T-DXd initiation to the date of T-DXd discontinuation, up to 14 months ]

Related Studies